TestMu AI, Soterion, and Kelun-Biotech announce new developments

Several companies have announced recent product developments and financial milestones.

TestMu AI has launched Agent Assurance, a tool designed to verify both conversational and autonomous AI agents. The product evaluates agents by generating test scenarios from code and grading actions against observed evidence, such as file changes and tool calls, rather than relying on an agent's own transcripts. It also introduces an ‘assurance gap’ metric to identify unverified actions.

Soterion reported that its SAP License Manager has completed 100 Full User Equivalent (FUE) assessments within one year of launch. The tool aims to help organizations manage costs associated with SAP’s STAR licensing framework by analyzing actual authorization usage rather than assigned access. Soterion noted that legacy role designs often overstated FUE requirements by approximately four times.

Kelun-Biotech announced its unaudited interim results for the period ending June 30, 2026. The company reported revenue of approximately RMB 978 million, with pharmaceutical product sales increasing 112% year-over-year to RMB 657 million. The growth is attributed to improved drug accessibility and clinical data recognition. The company continues to focus on Antibody-Drug Conjugate (ADC) and novel drug conjugate (DC) pipelines.